Radiochemistry Core

核心D项目总结 这一核心将使我们能够对我们的人性化形式的药物动力学和生物分布进行关键的洞察 通过提供89Zr-hAnnA1靶向抗体(HAnnA1)用于临床前和临床前的影像研究 首例人类临床试验。核心D放射化学核心的目标是标记抗体，用于 项目1和3。CORE D还将进行由CORE准备的89Zr-hAnnA1的试行成像研究 在cGMP条件下。基于hAnnA1的靶向成像具有很高的靶向亲和力和 导致偏离目标效应减少的专一性。当hAnnA1与放射性核素结合用于成像时， 可以开发新的放射性药物，以补充更传统的成像方式。 核心将使小窝泵送系统能够被评估其准确输送抗体的能力 用放射性核素直接标记成实体瘤和转移灶。 核心D将生产对项目1和3中的目标至关重要的放射性示踪剂，并将在 用于成像和治疗人类转移性疾病的新型精密递送放射性药物的开发。

CORE D PROJECT SUMMARY This Core will enable key insights into the pharmacokinetics and biodistribution of the humanized form of our Annexin A1 targeting antibody (hAnnA1) by providing 89Zr-hAnnA1 for imaging studies in both preclinical and a first-in-human clinical trial. The goal of the Core D Radiochemistry Core is to radiolabel antibodies for use in Projects 1 and 3. Core D will also conduct the pilot imaging study with 89Zr-hAnnA1 that is prepared by the Core under cGMP conditions. Imaging with hAnnA1-based targeting is promising due to high target affinity and specificity which leads to reduced off target effects. When hAnnA1 is conjugated to radionuclides for imaging, new radiopharmaceuticals can be developed which are complementary to more conventional imaging modalities. The Core will enable the caveolae pumping system to be evaluated for its ability to deliver precisely antibodies labeled with radionuclides directly into solid tumors and metastastic lesions. Core D will produce radiotracers essential to the aims in Projects 1 and 3, and will be instrumental in the development of novel precision delivered radiopharmaceuticals to image and treat metastatic disease in humans.